DOCSLIB.ORG

DOXORUBICIN Water for Injection USP and Doxorubicin Hydrochloride Injection Hydrochloric Acid USP for Ph Adjustment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DOXORUBICIN Water for Injection USP and Doxorubicin Hydrochloride Injection Hydrochloric Acid USP for Ph Adjustment IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION What the important non-medicinal ingredients are: Sodium Chloride USP, DOXORUBICIN Water for Injection USP and Doxorubicin hydrochloride injection Hydrochloric Acid USP for pH adjustment. This leaflet is part III of a three-part "Product What dosage form it comes in: Monograph" published when DOXORUBICIN was DOXORUBICIN injection 2 mg/mL (doxorubicin approved for sale in Canada and is designed specifically hydrochloride injection) is available in 10 mg (5mL), 50 for Consumers. This leaflet is a summary and will not mg (25mL) and 200 mg (100mL) contained in glass or tell you everything about DOXORUBICIN. Contact cytosafe (polypropylene) vials. your doctor or pharmacist if you have any questions about the drug. WARNINGS AND PRECAUTIONS ABOUT THIS MEDICATION If you are prescribed DOXORUBICIN it will only be given to you by doctors or nurses experienced in What the medication is used for: giving chemotherapy. DOXORUBICIN is used alone and in combination with other anti-cancer medication to produce regression of If you take DOXORUBICIN you may get: tumor in several cancer conditions. Damage to the heart muscle called heart failure. For the treatment of superficial bladder tumor, It is a decreased ability of the heart muscle to DOXORUBICIN is administered directly in the bladder. pump properly. This can lead to shortness of breath, swelling of the legs, irregular heart beat What it does: and sudden death. You are more likely to DOXORUBICIN is a chemotherapy drug, often used in develop this as the dose is increased. It may combination with other drugs to kill cancer cells. Most occur during treatment or up to several years chemotherapy agents (including DOXORUBICIN) work later. by killing rapidly dividing cells, such as cancer cells. This Risk of new cancers. You are at increased risk action can affect normal cells as well. for getting certain blood cancers. They are When it should not be used: called acute secondary myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). For intravenous administration: This can happen 1 to 3 years after treatment Allergy to doxorubicin hydrochloride or to any with DOXORUBICIN. It is more common if ingredient in the formulation or component of the you take it at higher doses or with other cancer container of DOXORUBICIN; treatments. This risk also applies to children. Allergy to other anthracyclines or anthracenediones such as epirubicin hydrochloride, daunorubicin Tissue damage. DOXORUBICIN will cause hydrochloride, mitoxantrone or mitomycin C; damage if it leaks out of your vein underneath your skin. You may get blisters or sores that Persistent low blood cell count (myelosuppression); require skin grafts. If it hurts, burns or sting in Severe liver disease; or around the vein into which the drug is being Severe heart disease; injected, tell the doctor or nurse Recent heart attack; IMMEDIATELY. Severe irregular heartbeat; History of severe cardiac disease; Low blood cell counts. DOXORUBICIN can Previous treatment with maximum cumulative doses of cause a severe decrease in the number of white doxorubicin, daunorubicin, epirubicin, idarubicin and/or blood cells, red blood cells, and platelets. This other anthracyclines and anthracenediones. means that you may bruise or bleed more easily, Accumulation of anthracycline doses may be harmful go into shock and need blood transfusions.You for your heart. may get fever, serious infection, and need treatment in a hospital. Low blood cell counts For intravesical administration: can lead to death. Your doctor will check your Blood in urine; blood cell counts during your treatment and Urinary tract infections; after you stop it. Call your doctor right away if Inflammation of the bladder. you get severe bleeding, fever or chills with shivering. What the medicinal ingredient is: Doxorubicin hydrochloride. Risk of liver problems. Tell your doctor if you have a history of liver disease. You should not take DOXORUBICIN if you have a severe liver disease. DOXORUBICIN (doxorubicin hydrochloride) Consumer Information Page 43 of 46 IMPORTANT: PLEASE READ BEFORE you use DOXORUBICIN talk to your doctor injected through the catheter or port rather than directly or pharmacist if: into a vein. you have low blood cell counts; you have a liver disease; Depending on your medical condition, you may also receive DOXORUBICIN by instillation into your you have a heart disease, recent heart attack or irregular bladder through a catheter inserted into the urinary heartbeat; natural tract. you are taking other drugs (including calcium channel blockers) or have been previously treated with How much time does it take to get a treatment with DOXORUBICIN or other anti-cancer drugs, including DOXORUBICIN? anthracyclines (cardiotoxic drugs); It usually takes about 3-10 minutes to inject you are pregnant, breast-feeding or planning to become DOXORUBICIN. However, you may get other pregnant. medicines before or after DOXORUBICIN, so your entire treatment may last an hour or longer. As DOXORUBICIN may be harmful to an unborn child, If you are administered DOXORUBICIN by instillation women should be advised to avoid becoming pregnant. into your bladder, the solution should generally be Effective contraceptive methods should be used. retained in your bladder for 1-2 hours prior to voiding. As DOXORUBICIN may cause fertility impairment and damage chromosomes in sperm, men undergoing treatment How long will I need treatment? with DOXORUBICIN should use effective contraceptive Your doctor will determine the length of your treatment methods. based on your medical condition, your treatment goals, the medicines you receive, and how your body responds to those medicines. INTERACTIONS WITH THIS MEDICATION Chemotherapy is usually given in cycles that include Combination chemotherapy regimens that contain other rest periods between treatments. The rest periods give agents with similar action may lead to additive toxicity, your body a chance to build healthy new cells and especially with regard to bone marrow/hematologic, regain your strength before your next treatment. gastrointestinal, and cardiac effects. DOXORUBICIN is usually given in treatment cycles of 21 days or 28 days. You may receive 1 dose of Administration of live vaccines to immunosuppressed DOXORUBICIN every 3 or 4 weeks (on Day 1 of the patients including those undergoing cytotoxic cycle). Alternately, you may also receive chemotherapy should be avoided. DOXORUBICIN instilled into your bladder weekly for 4 weeks and then monthly. Your treatment cycle will Drug interactions with DOXORUBICIN and the following depend on your medical condition and the other drugs have been reported in the literature: chemotherapy medicines you are getting. Paclitaxel; Phenobarbital; Will I be able to work? Some people work full time, while others work part Phenytoin; time or wait until their chemotherapy treatments are Streptozocin; finished. It depends on the type of job you have and the Cyclophosphamide; side effects you experience. Cyclosporine 6-mercaptopurine; Is it okay to become pregnant or nurse a baby? Actinomycin-D. No. DOXORUBICIN can be harmful to an unborn child. If there is any possibility that you may become PROPER USE OF THIS MEDICATION pregnant, ask your doctor about using birth control to prevent pregnancy during your treatment with DOXORUBICIN. Tell your doctor right away if you How is DOXORUBICIN given? become pregnant during treatment. If you have been You may receive DOXORUBICIN through a vein in the nursing, you should stop before starting treatment with arm (“intravenously” or “IV”) by your doctor or nurse, DOXORUBICIN. Ask your baby’s doctor to usually in the hospital, outpatient department or clinic. recommend a formula that would be best for your baby. If you are getting many injections over several weeks or months, for your convenience, your doctor may insert a catheter (thin tube) or port into a large vein in your body that is placed there as long as it is needed. Medicines get DOXORUBICIN (doxorubicin hydrochloride) Consumer Information Page 44 of 46 IMPORTANT: PLEASE READ What should men consider when taking SERIOUS SIDE EFFECTS, HOW OFTEN THEY DOXORUBICIN? Men undergoing treatment with doxorubicin should use HAPPEN AND WHAT TO DO ABOUT THEM effective contraceptive methods. Symptom / effect Talk with your doctor What happens after treatment? or pharmacist After you have completed all your chemotherapy Only if In all cases treatments, your doctor will check you regularly to make severe sure the cancer has not returned. Common anorexia diarrhea Overdosage: infection hemorrhage If you think you have been given more irregular heartbeat, DOXORUBICIN than you should, contact your chest pain, swelling doctor, nurse, or poison control centre immediately. of the ankles, shortness of breath / cardiac problems Missed Dose: If you miss your scheduled treatment with the drug, contact pain at the site of the injection your doctor as soon as possible to schedule your next rash/itch/redness/ treatment. skin allergy SIDE EFFECTS AND WHAT TO DO ABOUT THEM Un- loss of monthly common periods allergy/anaphylaxis Like all medicines, DOXORUBICIN can have side effects. blood clot Common side effects include: digestive hair loss, which is temporary and usually starts to grow inflammation, digestive tract back within 2 or 3 months after you have finished your bleeding (bloody treatments. stools, bloody increased risk
Load more

Recommended publications
  • August 2019: Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 39TH EDITION Cumulative Supplement Number 08 : August 2019 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE TABLET;ORAL APADAZ >D> + KVK TECH INC 325MG;EQ 8.16MG BASE N 208653 003 Jan 04, 2019 Aug CHRS >A> +! 325MG;EQ 8.16MG BASE N 208653 003 Jan 04, 2019 Aug CHRS ACETAMINOPHEN; CODEINE PHOSPHATE TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA ELITE LABS INC 300MG;15MG A 212418 001 Sep 10, 2019 Aug NEWA >A> AA 300MG;30MG A 212418 002 Sep 10, 2019 Aug NEWA >A> AA 300MG;60MG A 212418 003 Sep 10, 2019 Aug NEWA ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE TABLET;ORAL OXYCODONE AND ACETAMINOPHEN >D> AA CHEMO RESEARCH SL 325MG;5MG A 207574 001 Dec 13, 2016 Aug CAHN >A> AA HALO PHARM CANADA 325MG;5MG A 207834 001 Aug 15, 2019 Aug NEWA >A> AA 325MG;7.5MG A 207834 002 Aug 15, 2019 Aug NEWA >A> AA 325MG;10MG A 207834 003 Aug 15, 2019 Aug NEWA >A> AA XIROMED 325MG;5MG A 207574 001 Dec 13, 2016 Aug CAHN ACYCLOVIR CAPSULE;ORAL ACYCLOVIR >A> AB CADILA 200MG A 204313 001 Mar 25, 2016 Aug CAHN >D> AB ZYDUS PHARMS 200MG A 204313 001 Mar 25, 2016 Aug CAHN >D> OINTMENT;OPHTHALMIC >D> AVACLYR >D> +! FERA PHARMS LLC 3% N 202408 001 Mar 29, 2019 Aug DISC >A> + @ 3% N 202408 001 Mar 29, 2019 Aug DISC OINTMENT;TOPICAL ACYCLOVIR >A> AB APOTEX INC 5% A 210774 001 Sep 06, 2019 Aug NEWA >D> AB PERRIGO UK FINCO 5% A 205659 001 Feb 20, 2019 Aug DISC >A> @ 5% A 205659 001 Feb 20, 2019 Aug DISC ALBENDAZOLE TABLET;ORAL ALBENDAZOLE >A> AB STRIDES PHARMA 200MG A 210011
    [Show full text]
  • Induction with Mitomycin C, Doxorubicin, Cisplatin And
    British Journal of Cancer (1999) 80(12), 1962–1967 © 1999 Cancer Research Campaign Article no. bjoc.1999.0627 Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study RL Hong1, TS Sheen2, JY Ko2, MM Hsu2, CC Wang1 and LL Ting3 Departments of 1Oncology, 2Otolaryngology and 3Radiation Therapy, National Taiwan University Hospital, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10016, Taiwan Summary The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into this phase II trial. Mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin 60 mg m–2 were given on day 1 every 3 weeks as initial induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m–2 and leucovorin 30 mg m–2 for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had grade 4 leukopenia.
    [Show full text]
  • Arsenic Trioxide Is Highly Cytotoxic to Small Cell Lung Carcinoma Cells
    160 Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells 1 1 Helen M. Pettersson, Alexander Pietras, effect of As2O3 on SCLC growth, as suggested by an Matilda Munksgaard Persson,1 Jenny Karlsson,1 increase in neuroendocrine markers in cultured cells. [Mol Leif Johansson,2 Maria C. Shoshan,3 Cancer Ther 2009;8(1):160–70] and Sven Pa˚hlman1 1Center for Molecular Pathology, CREATE Health and 2Division of Introduction Pathology, Department of Laboratory Medicine, Lund University, 3 Lung cancer is the most frequent cause of cancer deaths University Hospital MAS, Malmo¨, Sweden; and Department of f Oncology-Pathology, Cancer Center Karolinska, Karolinska worldwide and results in 1 million deaths each year (1). Institute and Hospital, Stockholm, Sweden Despite novel treatment strategies, the 5-year survival rate of lung cancer patients is only f15%. Small cell lung carcinoma (SCLC) accounts for 15% to 20% of all lung Abstract cancers diagnosed and is a very aggressive malignancy Small cell lung carcinoma (SCLC) is an extremely with early metastatic spread (2). Despite an initially high aggressive form of cancer and current treatment protocols rate of response to chemotherapy, which currently com- are insufficient. SCLC have neuroendocrine characteristics bines a platinum-based drug with another cytotoxic drug and show phenotypical similarities to the childhood tumor (3, 4), relapses occur in the absolute majority of SCLC neuroblastoma. As multidrug-resistant neuroblastoma patients. At relapse, the efficacy of further chemotherapy is cells are highly sensitive to arsenic trioxide (As2O3) poor and the need for alternative treatments is obvious. in vitro and in vivo, we here studied the cytotoxic effects Arsenic-containing compounds have been used in tradi- of As2O3 on SCLC cells.
    [Show full text]
  • 5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
    Article Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells Maria Pereira-Oliveira, Ana Reis-Mendes, Félix Carvalho, Fernando Remião, Maria de Lourdes Bastos and Vera Marisa Costa * UCIBIO, REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; [email protected] (M.P.-O.); [email protected] (A.R.-M.); [email protected] (F.C.); [email protected] (F.R.); [email protected] (M.L.B.) * Correspondence: [email protected] Received: 4 October 2018; Accepted: 3 January 2019; Published: 10 January 2019 Abstract: Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as Adriamycin), 5-fluorouracil (5-FU), cyclophosphamide (CYA), and their combination (5-Fluorouracil + Adriamycin + Cyclophosphamide, FAC) in H9c2 cardiac cells, for a better understanding of the contribution of each drug to FAC-induced cardiotoxicity. Differentiated H9c2 cells were exposed to pharmacological relevant concentrations of DOX (0.13–5 μM), 5-FU (0.13–5 μM), CYA (0.13–5 μM) for 24 or 48 h. Cells were also exposed to FAC mixtures (0.2, 1 or 5 μM of each drug and 50 μM 5-FU + 1 μM DOX + 50 μM CYA). DOX was the most cytotoxic drug, followed by 5-FU and lastly CYA in both cytotoxicity assays (reduction of 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyl tetrazolium bromide (MTT) and neutral red (NR) uptake).
    [Show full text]
  • Characteristics of Doxorubicin‑Selected Multidrug‑Resistant Human Leukemia HL‑60 Cells with Tolerance to Arsenic Trioxide and Contribution of Leukemia Stem Cells
    ONCOLOGY LETTERS 15: 1255-1262, 2018 Characteristics of doxorubicin‑selected multidrug‑resistant human leukemia HL‑60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells JING CHEN, HULAI WEI, JIE CHENG, BEI XIE, BEI WANG, JUAN YI, BAOYING TIAN, ZHUAN LIU, FEIFEI WANG and ZHEWEN ZHANG Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu 730000, P.R. China Received December 29, 2015; Accepted June 9, 2017 DOI: 10.3892/ol.2017.7353 Abstract. The present study selected and characterized resistance (MDR) frequently induces therapy failure or tumor a multidrug-resistant HL-60 human acute promyelocytic recurrence (1-3). MDR involves various mechanisms including, leukemia cell line, HL-60/RS, by exposure to stepwise adenosine triphosphate-binding cassette (ABC) transporters, incremental doses of doxorubicin. The drug-resistant P-glycoprotein (P-gp), multidrug-resistance-related protein HL-60/RS cells exhibited 85.68-fold resistance to doxoru- (MRP) and breast-cancer-resistance protein (BCRP) overex- bicin and were cross-resistant to other chemotherapeutics, pression, which function to efflux certain molecules out of including cisplatin, daunorubicin, cytarabine, vincristine the cells (4-8). In addition, mechanisms of acquired MDR and etoposide. The cells over-expressed the transporters in leukemia also include abnormal drug metabolism and the P-glycoprotein, multidrug-resistance-related protein 1 presence of leukemia stem cells (LSC). LSCs are particu- and breast-cancer-resistance protein, encoded by the larly of interest and considered to serve an important role adenosine triphosphate-binding cassette (ABC)B1, ABCC1 in leukemia resistance and relapse (4).
    [Show full text]
  • Cyclophosphamide-Doxorubicin Ver
    Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOXORUBICIN Regimen Breast Cancer – Cyclophosphamide-Doxorubicin Indication Primary systemic (neoadjuvant) therapy of breast cancer Adjuvant therapy of high risk (greater than 5%) node negative breast cancer WHO Performance status 0, 1, 2 Toxicity Drug Adverse Effect Cyclophosphamide Dysuria, haemorrhagic cystitis, taste disturbances Doxorubicin Cardio toxicity, urinary discolourisation (red) The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Regimen FBC, U&E’s and LFT’s prior to each cycle. Ensure adequate cardiac function before starting treatment with doxorubicin. Baseline LVEF should be measured, particularly in patients with a history of cardiac problems or in the elderly. Dose Modifications The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re- escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Version 1.1 (Aug 2014) Page 1 of 6 Breast – Cyclophosphamide-Doxorubicin Please discuss all dose reductions / delays with the relevant consultant before prescribing if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Haematological Prior to prescribing the following treatment criteria must be met on day 1 of treatment. Criteria Eligible Level Neutrophil equal to or more than 1x109/L Platelets equal to or more than 100x109/L Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL If counts on day one are below these criteria for neutrophil and/or platelets then delay treatment for seven days.
    [Show full text]
  • Combination Chemotherapy with Estramustine Phosphate, Ifosfamide and Cisplatin for Hormone-Refractory Prostate Cancer
    Acta Med. Okayama, 2006 Vol. 60, No. 1, pp. 43ﾝ49 CopyrightⒸ 2006 by Okayama University Medical School. Original Article http ://www.lib.okayama-u.ac.jp/www/acta/ Combination Chemotherapy with Estramustine Phosphate, Ifosfamide and Cisplatin for Hormone-refractory Prostate Cancer Haruki Kakua, Takashi Saikaa＊, Tomoyasu Tsushimab, Atsushi Nagaia, Teruhiko Yokoyamaa, Fernando Abarzuaa, Shin Ebaraa, Daisuke Manabea, Yasutomo Nasua, and Hiromi Kumona aDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700ﾝ8558, Japan, and bDepartment of Urology, Medival center of Okayama, Okayama 701-1192, Japan We evaluated the effi ciency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and cis- platin (CDDP) combination chemotherapy in twenty-one patients with hormone-refractory prostate cancer (HRPC), for which there is currently no eff ective treatment. Patients received a daily dose of 560 mg ECT in combination with 1.2 g/m2 IFM on days 1 to 5 and 70 mg/m2 CDDP on day 1. This combination therapy was given every 3 to 4 weeks. An objective response of more than 50ｵ reduc- tion in prostate-specifi c antigen was observed in 9 of 18 patients (50ｵ), and a more than 50ｵ reduc- tion in bi-dimensionally measurable soft-tissue lesions was observed in 2 of 7 patients (29ｵ). The median duration of response among the cases showing partial response was 40 weeks, while the median duration of response of overall partial-response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable. In conclusion, the ECT, IFM and CDDP combination chemotherapy regimen is a viable treatment option for HRPC.
    [Show full text]
  • Chemotherapy Protocol
    Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-DOXORUBICIN (TAC) Regimen Breast Cancer – Cyclophosphamide-Docetaxel-Doxorubicin (TAC) Indication Adjuvant therapy for node positive early breast cancer WHO Performance status 0, 1, 2 Toxicity Drug Adverse Effect Cyclophosphamide Dysuria, haemorrhagic cystitis, taste disturbances Hypersensitivity, fluid retention, neuropathy, joint pains, nail Docetaxel changes, fatigue Doxorubicin Cardio toxicity, urinary discolourisation (red) The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Regimen FBC, U&E’s and LFT’s prior to each cycle. Ensure adequate cardiac function before starting treatment. Baseline LVEF should be measured, particularly in patients with a history of cardiac problems or in the elderly. Dose Modifications The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re- escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Version 1.1 (Aug 2014) Page 1 of 8 Breast – Cyclophosphamide-Docetaxel-Doxorubicin (TAC) Please discuss all dose reductions / delays with the relevant consultant before prescribing if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Haematological Prior to prescribing the following treatment criteria must be met on day one of treatment. Criteria Eligible Level Neutrophil equal to or more than 1x109/L Platelets equal to or more than 100x109/L Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL If counts on day one are below these criteria for neutrophils and/or platelets then delay treatment for seven days.
    [Show full text]
  • SAVACM Protocol
    BC Cancer Protocol Summary for the Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using vinCRIStine, DOXOrubicin, Cyclophosphamide and Mesna Protocol Code SAVACM Tumour Group Sarcoma Contact Physician Dr. Christine Simmons ELIGIBILITY: . Ewing’s sarcoma/peripheral neuroectodermal tumour or rhabdomyosarcoma in pelvic sites or pediatric type small round blue cell tumours in patients for whom alternating protocol is not appropriate where treatment includes pelvic radiotherapy . Patients with hematuria due to ifosfamide or cyclophosphamide . Good performance status . Adequate bone marrow, liver and kidney function TESTS: . Baseline and before each treatment: CBC and diff, platelets, creatinine, bilirubin, ALT, alkaline phosphatase, GGT, LDH . Urine dipstick for blood before each treatment and every 8 hours during treatment – if positive at any time, notify doctor and send urine sample for urinalysis and verification and accurate determination - refer to supportive care protocol SCMESNA (follow SCMESNA (SAVACM) preprinted order) . If clinically indicated: ECG PREMEDICATIONS: . Antiemetic protocol for highly emetogenic chemotherapy protocols (see SCNAUSEA) . LORazepam 1 mg SL every 4 to 6 hours as needed . prochlorperazine 10 mg PO every 4 to 6 hours as needed . nabilone 1 mg PO every 6 to 8 hours as needed TREATMENT: . Repeat every 3 weeks. SAVACM is not given during radiotherapy; omit DOXOrubicin and continue with vinCRIStine, cyclophosphamide and mesna. BC Cancer Protocol Summary SAVACM Page 1 of 3 Activated: N/A Revised: 1 Apr 2021 (prochlorperazine route) Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment.
    [Show full text]
  • Protocol Code: BRAJACTW Tumour Group: Breast Contact Physician: Dr
    BC Cancer Protocol Summary for Neoadjuvant or Adjuvant Therapy for Early Breast Cancer Using DOXOrubicin and Cyclophosphamide followed by Weekly PACLitaxel Protocol Code: BRAJACTW Tumour Group: Breast Contact Physician: Dr. Caroline Lohrisch ELIGIBILITY: A number of studies suggest that the schedule of delivery of PACLitaxel is important in maximizing efficacy. The preferred delivery method of PACLitaxel after AC chemotherapy is either every two weeks with G-CSF (see protocol BRAJACTG) or weekly for 12 weeks, as described in this protocol. Neoadjuvant or adjuvant treatment for 1 or more axillary lymph node metastasis(es), or node negative but with high risk of recurrence EXCLUSIONS: . Pregnancy . Severe cardiovascular disease with LVEF less than 55% . AST and/or ALT greater than 10 times the Upper Limit of Normal (ULN) . total bilirubin greater than 128 micromol/L TESTS: . Baseline and Prior to Cycle #5: CBC & diff, platelets, bilirubin, ALT . Baseline if clinically indicated: alk phos, LDH, GGT . Before each treatment: CBC & diff, platelets . If clinically indicated: bilirubin, ALT, creatinine PREMEDICATIONS: . For the 4 cycles of DOXOrubicin and cyclophosphamide: Antiemetic protocol for highly emetogenic chemotherapy (see protocol SCNAUSEA) . For the 4 cycles (=12 weeks) of PACLitaxel: PACLitaxel must not be started unless the following drugs have been given: 45 minutes prior to PACLitaxel: . dexamethasone 10 mg IV in 50 mL NS over 15 minutes 30 minutes prior to PACLitaxel: . diphenhydrAMINE 25 mg IV in NS 50 mL over 15 minutes and famotidine 20 mg IV in NS 100 mL over 15 minutes (Y-site compatible) . If no PACLitaxel infusion reactions occur, no premedications may be needed for subsequent PACLitaxel doses and may be omitted at physician’s discretion.
    [Show full text]
  • Multiple Myeloma
    MULTIPLE MYELOMA ARSENIC TRIOXIDE Arsenic trioxide 0.25 mg/kg/day IV* Monday - Friday of Weeks 1 and 2** *Administer over 1 hour; **Administer Monday - Friday (5 days per week) during the first 2 weeks of each 4 week cycle. Repeat cycles every 28 days. NOTE: Ensure that serum electrolytes are assessed and corrected, particularly potassium and magnesium, prior to start of treatment, and maintain these values throughout the cycle. Avoid medication known to prolong the QTc interval. Obtain a 12-lead ECG prior to the first dose and ensure that the QTc interval is not greater than 460 msec. Reference: Hussein MA, et al. Br J Haematol 2004;125:470 - 6. BORTEZOMIB Bortezomib 1.3 mg/m2 IVB Days 1, 4, 8 and 11 Repeat cycle every 21 days to a maximum of 8 cycles. NOTE: Patients with progressive disease after 2 cycles or stable diseases after 4 cycles were able to receive dexamethasone 20 mg on the day of and the day after bortezomib. Reference: Richardson PG, et al. N Engl J Med 2003;348:2609 – 17. BORTEZOMIB – DOXORUBICIN - DEXAMETHASONE Bortezomib 1.3 mg/m2 IVB Days 1, 4, 8 and 11 Dexamethasone 40 mg /day PO See below (cycle dependent) Doxorubicin 9 mg/m2/day IV Days 1 - 4 Repeat cycle every 21 days for 4 cycles. NOTE: Dexamethasone dosing: 40 mg PO/day was administered on days 1 – 4, 8 – 11, and 15 – 18 of cycle 1 and on days 1 – 4 of cycles 2 – 4. Concurrent bisphosphonate therapy, gastric protection, erythropoietin and Pneumocystis carinii prophylaxis were given.
    [Show full text]
  • Doxorubicin Liposome (Doxil®) Pronounced: “Doks-Oh-ROO-Bi-Sin Lye-Po-Soam”
    Doxorubicin Liposome Chemotherapy: Doxorubicin Liposome (Doxil®) Pronounced: “doks-oh-ROO-bi-sin lye-po-soam” How drug is given: By vein (IV) Purpose: To stop the growth of cancer cells in many different types of cancer. This drug is a special form of the cancer drug doxorubicin, mixed in a special solution of liposomes (“fat bodies”). Things that may occur during or within hours of treatment • An allergic reaction may occur. Tell your cancer care team right away if you have fever, chills, chest pain, trouble breathing, itching, rash, or dizziness. This can be life threatening. • You may be given drugs before you start doxorubicin liposome that will try to keep this from happening. You may be asked to take dexamethasone (a steroid) at home before you start treatment. • Your blood pressure may drop, or your heart rate may slow down while you are getting this drug. You might feel lightheaded or dizzy. This usually goes back to normal on its own. It is important to ask for assistance and take your time when you stand up during or after your treatment. • If you feel any burning or tingling near your IV, please tell your nurse right away. If you develop any swelling or redness after you go home, call your cancer care team right away. Things that may occur a few days to weeks later • Mild to moderate nausea, vomiting, and loss of appetite may occur. You may be given drugs to help with this. • Some of your hair may thin and fall out with treatment. • Tingling and peeling of the skin may occur.
    [Show full text]